

CLAIMS

1. (Deleted)

2. (Deleted)

5 3. (Deleted)


4. (Deleted)

5. (Deleted)


6. (Deleted)

7. (Deleted)



10 8. (Amended) A compound of the formula (I):




wherein



is



, or



15

R^1 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$ or $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$;

R^2 is hydrogen or alkyl;

m is 0 or 1;

p is 0 or 1, provided that when $p = 0$, X^1 is not bonded to X^3 via X^4 ;


20 X^1 and X^3 each is independently optionally substituted aryl or optionally substituted heteroaryl;

X^2 is a bond, $-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{NH}-$, $-\text{N}(\text{CH}_3)-$, $-\text{C}(=\text{N}-\text{O}-$


CH_3)-, $-\text{N}=\text{N}-$, $-\text{CH}=\text{CH}-$, $-(\text{C}=\text{O})-\text{NH}-$, $-\text{NH}-(\text{C}=\text{O})-$, $-\text{CH}_2-\text{NH}-$, $-\text{NH}-\text{CH}_2-$, $-\text{CH}_2-\text{O}-$, $-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-$, $-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{SO}_2-$, $-\text{SO}_2-\text{CH}_2-$, $-\text{SO}_2-\text{NH}-$ or $-\text{NH}-\text{SO}_2-$;

X^4 is $-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{SO}-$, $-\text{SO}_2-$, $-(\text{C}=\text{O})-\text{NH}-$, $-\text{NH}-(\text{C}=\text{O})-$, $-\text{CH}_2-\text{NH}-$, $-\text{NH}-\text{CH}_2-$, $-\text{CH}_2-\text{O}-$, $-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-$, $-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{SO}_2-$, $-\text{SO}_2-\text{CH}_2-$, $-\text{SO}_2-\text{NH}-$ or $-\text{NH}-\text{SO}_2-$;


5 provided that when



is




10 a compound wherein R^1 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$, R^2 is hydrogen or methyl, m is 0, p is 0, X^1 is phenyl optionally substituted with methoxy, X^2 is a bond, $-\text{O}-$, $-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{NH}-$, $-\text{S}-$ or $-\text{N}=\text{N}-$, and X^3 is phenyl optionally substituted with hydroxy, acetoxy or methoxy, and a compound wherein R^1 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOH}$, m is 1, p is 0, X^1 is phenyl, X^2 is $-\text{N}=\text{N}-$, and X^3 is phenyl, are excluded, and when



15

is



20 R^1 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOR}^2$, R^2 is hydrogen or methyl, m is 0, and p is 0, a compound wherein X^1 is phenyl optionally substituted with methyl or methoxy, X^2 is a bond, $-\text{CH}_2-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{NH}-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CH}=\text{CH}-$, $-\text{N}=\text{N}-$, $-\text{C}(=\text{O})-\text{NH}-$ or $-\text{NH}-\text{C}(=\text{O})-$, and X^3 is phenyl optionally substituted with methyl, hydroxy, acetoxy, methoxy, ethoxy, isopropoxy, dimethylamino, hydroxymethyl, methoxymethyl or

347 2A ANDT

carboxy, a compound wherein X^1 is phenyl, X^2 is a bond, $-CH_2-$ or $-CH=CH-$, and X^3 is imidazolyl, thienyl, pyridyl or tetrazolyl optionally substituted with methyl or phenyl, and a compound wherein X^1 is benzothienyl, isoxazolyl or thienyl optionally substituted with methyl, X^2 is a bond or $-S-$, and X^3 is phenyl optionally substituted with methoxy or methyl, are excluded, a prodrug, a pharmaceutically acceptable salt, a hydrate thereof.

9. The compound according to claim 8 wherein at least one of X^1 and X^3 is optionally substituted heteroaryl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

10. The compound according to claim 8 wherein X^1 and X^3 each is independently optionally substituted heteroaryl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

11. The compound according to claim 8 wherein at least one of X^1 and X^3 is optionally substituted thienyl or optionally substituted benzothienyl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

12. The compound according to any one of claims 8 to 11 wherein X^2 is a bond, $-CH_2-$, $-S-$, $-SO_2-$, $-CH_2-O-$, $-O-CH_2-$, $-CH_2-S-$ or $-S-CH_2-$, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

13. The compound according to any one of claims 8 to 12 wherein R^1 is $-CH_2-CH=CH-CH_2-CH_2-CH_2-COOH$, m is 0, and p is 0, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

14. A pharmaceutical composition which comprises a compound according to any one of claims 8 to 13.

15. A pharmaceutical composition having a dual antagonistic activity against PGD_2/TXA_2 receptors which comprises a compound according to any one of claims 8 to

13.

16. The pharmaceutical composition comprising a compound according to claim 14 or 15, which is used for asthma.

17. The pharmaceutical composition comprising a compound according to claim 14 or 15, which is used for nasal blockage.

18. (Added) Use of the compound according to any one of claims 8 to 13 for

manufacturing a pharmaceutical composition for asthma or nasal blockage.

19. (Added) A method for treating asthma or nasal blockage which comprises administering the compound according to any one of claims 8 to 13.

FOOTNOTES: FOOTNOTES